KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Receivables (2016 - 2025)

Chemed (CHE) has 17 years of Receivables data on record, last reported at $191.2 million in Q4 2025.

  • For Q4 2025, Receivables rose 6.26% year-over-year to $191.2 million; the TTM value through Dec 2025 reached $191.2 million, up 6.26%, while the annual FY2025 figure was $191.2 million, 6.26% up from the prior year.
  • Receivables reached $191.2 million in Q4 2025 per CHE's latest filing, down from $223.7 million in the prior quarter.
  • Across five years, Receivables topped out at $287.4 million in Q1 2025 and bottomed at $104.7 million in Q1 2021.
  • Average Receivables over 5 years is $163.4 million, with a median of $162.6 million recorded in 2023.
  • Peak YoY movement for Receivables: decreased 22.23% in 2021, then soared 60.22% in 2025.
  • A 5-year view of Receivables shows it stood at $139.1 million in 2021, then grew by 1.53% to $141.2 million in 2022, then rose by 29.7% to $183.2 million in 2023, then dropped by 1.76% to $180.0 million in 2024, then rose by 6.26% to $191.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $191.2 million in Q4 2025, $223.7 million in Q3 2025, and $186.4 million in Q2 2025.